Advertisement

Obesity pp 179-194 | Cite as

Obesity and NAFLD

  • Paul Cordero
  • Jiawei Li
  • Jude A. Oben
Reference work entry
Part of the Endocrinology book series (ENDOCR)

Abstract

Obesity is currently considered the main health challenge of the twenty-first century. It is a chronic pro-inflammatory disease which systemically affects normal physiology and metabolism, causing multiple associated diseases such as cardiovascular disease, diabetes, nonalcoholic fatty liver disease (NAFLD), and several types of cancer, among others. The main contributors for NAFLD development and progression include high concentrations of diet and adipose tissue-derived free fatty acids and pro-inflammatory adipocytokines. These fatty acids are released from adipocytes and/or from dietary intake and are delivered to the liver. The fatty acids in the hepatocytes can then be oxidized by the mitochondria or converted into triglycerides for intracellular accumulation. With elevated mitochondrial oxidation levels, there is an overproduction of reactive oxygen species and other species that mediate hepatic injury, inflammation, and apoptosis. In order to manage obesity and NAFLD, nutritionally based body weight management is the principal modifiable risk factor. Thus, dietary interventions for body weight loss should be the main therapeutic approach, although pharmacotherapy and, in some specific situation, surgical or bariatric endoscopic interventions may be necessary.

Keywords

Obesity Nonalcoholic fatty liver disease Metabolic syndrome Nonalcoholic steatohepatitis Intra-abdominal fat Fatty liver Insulin resistance Fatty acids Steatosis 

References

  1. Abdelaal M, le Roux CW, Docherty NG. Morbidity and mortality associated with obesity. Ann Transl Med. 2017;5:161.PubMedPubMedCentralCrossRefGoogle Scholar
  2. Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66:1138–53.PubMedCrossRefGoogle Scholar
  3. Aguilar-Olivos NE, Almeda-Valdes P, Aguilar-Salinas CA, Uribe M, Mendez-Sanchez N. The role of bariatric surgery in the management of nonalcoholic fatty liver disease and metabolic syndrome. Metabolism. 2016;65:1196–207.PubMedCrossRefGoogle Scholar
  4. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846–54.PubMedCrossRefGoogle Scholar
  5. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389–97. e310PubMedPubMedCentralCrossRefGoogle Scholar
  6. Apovian CM, Aronne LJ. The 2013 American Heart Association/American College of Cardiology/The Obesity Society Guideline for the management of overweight and obesity in adults: what is new about diet, drugs, and surgery for obesity? Circulation. 2015;132:1586–91.PubMedCrossRefGoogle Scholar
  7. Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, Hazlehurst JM, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387:679–90.PubMedCrossRefGoogle Scholar
  8. Asada K, Aihara Y, Takaya H, Noguchi R, Namisaki T, Moriya K, Uejima M, et al. DNA methylation of angiotensin II receptor gene in nonalcoholic steatohepatitis-related liver fibrosis. World J Hepatol. 2016;8:1194–9.PubMedPubMedCentralCrossRefGoogle Scholar
  9. Asghari G, Mirmiran P, Yuzbashian E, Azizi F. A systematic review of diet quality indices in relation to obesity. Br J Nutr. 2017;117:1055–65.PubMedCrossRefGoogle Scholar
  10. Bertolotti M, Lonardo A, Mussi C, Baldelli E, Pellegrini E, Ballestri S, Romagnoli D, et al. Nonalcoholic fatty liver disease and aging: epidemiology to management. World J Gastroenterol. 2014;20:14185–204.PubMedPubMedCentralCrossRefGoogle Scholar
  11. Bird A. Perceptions of epigenetics. Nature. 2007;447:396–8.PubMedCrossRefGoogle Scholar
  12. Brandl K, Schnabl B. Intestinal microbiota and nonalcoholic steatohepatitis. Curr Opin Gastroenterol. 2017;33:128–33.PubMedPubMedCentralCrossRefGoogle Scholar
  13. Bruckbauer A, Banerjee J, Fu L, Li F, Cao Q, Cui X, Wu R, et al. A combination of leucine, metformin, and sildenafil treats nonalcoholic fatty liver disease and steatohepatitis in mice. Int J Hepatol. 2016;2016:9185987.PubMedPubMedCentralCrossRefGoogle Scholar
  14. Carter R, Mouralidarane A, Ray S, Soeda J, Oben J. Recent advancements in drug treatment of obesity. Clin Med (Lond). 2012;12:456–60.CrossRefGoogle Scholar
  15. Catalano PM, Shankar K. Obesity and pregnancy: mechanisms of short term and long term adverse consequences for mother and child. BMJ. 2017;356:j1.PubMedCrossRefGoogle Scholar
  16. Chakravarthy MV, Booth FW. Eating, exercise, and “thrifty” genotypes: connecting the dots toward an evolutionary understanding of modern chronic diseases. J Appl Physiol (1985). 2004;96:3–10.CrossRefGoogle Scholar
  17. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142:1592–609.PubMedCrossRefGoogle Scholar
  18. Cordero P, Campion J, Milagro FI, Goyenechea E, Steemburgo T, Javierre BM, Martinez JA. Leptin and TNF-alpha promoter methylation levels measured by MSP could predict the response to a low-calorie diet. J Physiol Biochem. 2011a;67:463–70.PubMedCrossRefGoogle Scholar
  19. Cordero P, Campion J, Milagro FI, Martinez JA. Dietary supplementation with methyl donor groups could prevent nonalcoholic fatty liver. Hepatology. 2011b;53:2151–2.PubMedCrossRefGoogle Scholar
  20. Cordero P, Campion J, Milagro FI, Martinez JA. Transcriptomic and epigenetic changes in early liver steatosis associated to obesity: effect of dietary methyl donor supplementation. Mol Genet Metab. 2013a;110:388–95.PubMedCrossRefGoogle Scholar
  21. Cordero P, Gomez-Uriz AM, Campion J, Milagro FI, Martinez JA. Dietary supplementation with methyl donors reduces fatty liver and modifies the fatty acid synthase DNA methylation profile in rats fed an obesogenic diet. Genes Nutr. 2013b;8:105–13.PubMedCrossRefGoogle Scholar
  22. Cordero P, Milagro FI, Campion J, Martinez JA. Supplementation with methyl donors during lactation to high-fat-sucrose-fed dams protects offspring against liver fat accumulation when consuming an obesogenic diet. J Dev Orig Health Dis. 2014;5:385–95.PubMedCrossRefGoogle Scholar
  23. Cordero P, Li J, Oben JA. Epigenetics of obesity: beyond the genome sequence. Curr Opin Clin Nutr Metab Care. 2015a;18:361–6.PubMedCrossRefGoogle Scholar
  24. Cordero P, Gonzalez-Muniesa P, Milagro FI, Campion J, Martinez JA. Perinatal maternal feeding with an energy dense diet and/or micronutrient mixture drives offspring fat distribution depending on the sex and growth stage. J Anim Physiol Anim Nutr (Berl). 2015b;99:834–40.CrossRefGoogle Scholar
  25. Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology. 1998;114:842–5.PubMedCrossRefGoogle Scholar
  26. de Mesquita FC, Guixe-Muntet S, Fernandez-Iglesias A, Maeso-Diaz R, Vila S, Hide D, Ortega-Ribera M, et al. Liraglutide improves liver microvascular dysfunction in cirrhosis: evidence from translational studies. Sci Rep. 2017;7:3255.PubMedPubMedCentralCrossRefGoogle Scholar
  27. Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol. 2014;28:637–53.PubMedCrossRefGoogle Scholar
  28. DiMaria-Ghalili RA, Gilbert K, Lord L, Neal T, Richardson D, Tyler R, Guenter P, et al. Standards of nutrition care practice and professional performance for nutrition support and generalist nurses. Nutr Clin Pract. 2016;31:527–47.PubMedCrossRefGoogle Scholar
  29. Doulberis M, Kotronis G, Gialamprinou D, Kountouras J, Katsinelos P. Non-alcoholic fatty liver disease: an update with special focus on the role of gut microbiota. Metabolism. 2017;71:182–97.PubMedCrossRefGoogle Scholar
  30. Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, Sebastiani G, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65:1557–65.PubMedPubMedCentralCrossRefGoogle Scholar
  31. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865–73.PubMedCrossRefPubMedCentralGoogle Scholar
  32. European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388–402.Google Scholar
  33. Gallicchio L, Chang HH, Christo DK, Thuita L, Huang HY, Strickland P, Ruczinski I, et al. Single nucleotide polymorphisms in obesity-related genes and all-cause and cause-specific mortality: a prospective cohort study. BMC Med Genet. 2009;10:103.PubMedPubMedCentralCrossRefGoogle Scholar
  34. Gelli C, Tarocchi M, Abenavoli L, Di Renzo L, Galli A, De Lorenzo A. Effect of a counseling-supported treatment with the Mediterranean diet and physical activity on the severity of the non-alcoholic fatty liver disease. World J Gastroenterol. 2017;23:3150–62.PubMedPubMedCentralCrossRefGoogle Scholar
  35. Goni L, Milagro FI, Cuervo M, Martinez JA. Single-nucleotide polymorphisms and DNA methylation markers associated with central obesity and regulation of body weight. Nutr Rev. 2014;72:673–90.PubMedCrossRefPubMedCentralGoogle Scholar
  36. Gonzalez-Muniesa P, Martinez-Gonzalez MA, Hu FB, Despres JP, Matsuzawa Y, Loos RJF, Moreno LA, et al. Obesity. Nat Rev Dis Primers. 2017;3:17034.PubMedCrossRefPubMedCentralGoogle Scholar
  37. Hadizadeh F, Faghihimani E, Adibi P. Nonalcoholic fatty liver disease: diagnostic biomarkers. World J Gastrointest Pathophysiol. 2017;8:11–26.PubMedPubMedCentralCrossRefGoogle Scholar
  38. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008;57:1441–7.PubMedCrossRefGoogle Scholar
  39. Haslam DW, James WP. Obesity. Lancet. 2005;366:1197–209.PubMedCrossRefGoogle Scholar
  40. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, Hu FB, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014;63:2985–3023.PubMedCrossRefGoogle Scholar
  41. Jojima T, Tomotsune T, Iijima T, Akimoto K, Suzuki K, Aso Y. Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes. Diabetol Metab Syndr. 2016;8:45.PubMedPubMedCentralCrossRefGoogle Scholar
  42. Jortberg B, Myers E, Gigliotti L, Ivens BJ, Lebre M, Burke March S, Nogueira I, et al. Academy of nutrition and dietetics: standards of practice and standards of professional performance for registered dietitian nutritionists (competent, proficient, and expert) in adult weight management. J Acad Nutr Diet. 2015;115:609–18. e640PubMedCrossRefGoogle Scholar
  43. Kalia HS, Gaglio PJ. The prevalence and pathobiology of nonalcoholic fatty liver disease in patients of different races or ethnicities. Clin Liver Dis. 2016;20:215–24.PubMedCrossRefGoogle Scholar
  44. Kini S, Herron DM, Yanagisawa RT. Bariatric surgery for morbid obesity – a cure for metabolic syndrome? Med Clin North Am. 2007;91:1255–71. xiPubMedCrossRefGoogle Scholar
  45. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.PubMedCrossRefGoogle Scholar
  46. Kohan L, Safarpur M, Abdollahi H. Omentin-1 rs2274907 and resistin rs1862513 polymorphisms influence genetic susceptibility to nonalcoholic fatty liver disease. Mol Biol Res Commun. 2016;5:11–7.PubMedPubMedCentralGoogle Scholar
  47. Koukias N, Buzzetti E, Tsochatzis EA. Intestinal hormones, gut microbiota and non-alcoholic fatty liver disease. Minerva Endocrinol. 2017;42:184–94.PubMedGoogle Scholar
  48. Krawczyk M, Rau M, Schattenberg JM, Bantel H, Pathil A, Demir M, Kluwe J, et al. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study. J Lipid Res. 2017;58:247–55.PubMedCrossRefGoogle Scholar
  49. Laing P, Pham T, Taylor LJ, Fang J. Filling the void: a review of intragastric balloons for obesity. Dig Dis Sci. 2017;62:1399–408.PubMedCrossRefGoogle Scholar
  50. Lapadat AM, Jianu IR, Ungureanu BS, Florescu LM, Gheonea DI, Sovaila S, Gheonea IA. Non-invasive imaging techniques in assessing non-alcoholic fatty liver disease: a current status of available methods. J Med Life. 2017;10:19–26.PubMedPubMedCentralGoogle Scholar
  51. Li J, Cordero P, Nguyen V, Oben JA. The role of vitamins in the pathogenesis of non-alcoholic fatty liver disease. Integr Med Insights. 2016;11:19–25.PubMedPubMedCentralCrossRefGoogle Scholar
  52. Lichtinghagen R, Pietsch D, Bantel H, Manns MP, Brand K, Bahr MJ. The enhanced liver fibrosis (ELF) score: normal values, influence factors and proposed cut-off values. J Hepatol. 2013;59:236–42.PubMedCrossRefGoogle Scholar
  53. Lin X, Zhang Z, Chen JM, Xu YY, Ye HR, Cui J, Fang Y, et al. Role of APN and TNF-alpha in type 2 diabetes mellitus complicated by nonalcoholic fatty liver disease. Genet Mol Res. 2015;14:2940–6.PubMedCrossRefGoogle Scholar
  54. Madden AM, Smith S. Body composition and morphological assessment of nutritional status in adults: a review of anthropometric variables. J Hum Nutr Diet. 2016;29:7–25.PubMedCrossRefGoogle Scholar
  55. Milagro FI, Campion J, Cordero P, Goyenechea E, Gomez-Uriz AM, Abete I, Zulet MA, et al. A dual epigenomic approach for the search of obesity biomarkers: DNA methylation in relation to diet-induced weight loss. FASEB J. 2011;25:1378–89.PubMedCrossRefGoogle Scholar
  56. Milic S, Lulic D, Stimac D. Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. World J Gastroenterol. 2014;20:9330–7.PubMedPubMedCentralGoogle Scholar
  57. Moore JB. Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome. Proc Nutr Soc. 2010;69:211–20.PubMedCrossRefGoogle Scholar
  58. Motamed N, Rabiee B, Hemasi GR, Ajdarkosh H, Khonsari MR, Maadi M, Keyvani H, et al. Body roundness index and waist-to-height ratio are strongly associated with non-alcoholic fatty liver disease: a population-based study. Hepat Mon. 2016a;16:e39575.PubMedPubMedCentralGoogle Scholar
  59. Motamed N, Sohrabi M, Ajdarkosh H, Hemmasi G, Maadi M, Sayeedian FS, Pirzad R, et al. Fatty liver index vs waist circumference for predicting non-alcoholic fatty liver disease. World J Gastroenterol. 2016b;22:3023–30.PubMedPubMedCentralCrossRefGoogle Scholar
  60. Mouralidarane A, Soeda J, Sugden D, Bocianowska A, Carter R, Ray S, Saraswati R, et al. Maternal obesity programs offspring non-alcoholic fatty liver disease through disruption of 24-h rhythms in mice. Int J Obes. 2015;39:1339–48.CrossRefGoogle Scholar
  61. Neel JV, Weder AB, Julius S. Type II diabetes, essential hypertension, and obesity as “syndromes of impaired genetic homeostasis”: the “thrifty genotype” hypothesis enters the 21st century. Perspect Biol Med. 1998;42:44–74.PubMedCrossRefGoogle Scholar
  62. Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med. 2017;15:45.PubMedPubMedCentralCrossRefGoogle Scholar
  63. Petaja EM, Yki-Jarvinen H. Definitions of normal liver fat and the association of insulin sensitivity with acquired and genetic NAFLD-A systematic review. Int J Mol Sci. 2016;17.PubMedCentralCrossRefPubMedGoogle Scholar
  64. Poitou C, Perret C, Mathieu F, Truong V, Blum Y, Durand H, Alili R, et al. Bariatric surgery induces disruption in inflammatory signaling pathways mediated by immune cells in adipose tissue: a RNA-Seq study. PLoS One. 2015;10:e0125718.PubMedPubMedCentralCrossRefGoogle Scholar
  65. Poston L, Caleyachetty R, Cnattingius S, Corvalan C, Uauy R, Herring S, Gillman MW. Preconceptional and maternal obesity: epidemiology and health consequences. Lancet Diabetes Endocrinol. 2016;4:1025–36.PubMedCrossRefGoogle Scholar
  66. Rankinen T, Zuberi A, Chagnon YC, Weisnagel SJ, Argyropoulos G, Walts B, Perusse L, et al. The human obesity gene map: the 2005 update. Obesity (Silver Spring). 2006;14:529–644.CrossRefGoogle Scholar
  67. Satapathy SK, Sanyal AJ. Epidemiology and natural history of nonalcoholic fatty liver disease. Semin Liver Dis. 2015;35:221–35.PubMedCrossRefGoogle Scholar
  68. Schmatz R, Bitencourt MR, Patias LD, Beck M, CAG d, Zanini D, Gutierres JM, et al. Evaluation of the biochemical, inflammatory and oxidative profile of obese patients given clinical treatment and bariatric surgery. Clin Chim Acta. 2017;465:72–9.PubMedCrossRefGoogle Scholar
  69. Selvakumar PKC, Kabbany MN, Nobili V, Alkhouri N. Nonalcoholic fatty liver disease in children: hepatic and extrahepatic complications. Pediatr Clin North Am. 2017;64:659–75.PubMedCrossRefPubMedCentralGoogle Scholar
  70. Spahis S, Delvin E, Borys JM, Levy E. Oxidative stress as a critical factor in nonalcoholic fatty liver disease pathogenesis. Antioxid Redox Signal. 2017;26:519–41.PubMedCrossRefGoogle Scholar
  71. Takaki A, Kawai D, Yamamoto K. Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH). Int J Mol Sci. 2013;14:20704–28.PubMedPubMedCentralCrossRefGoogle Scholar
  72. Testelmans D, Tamisier R, Barone-Rochette G, Baguet JP, Roux-Lombard P, Pepin JL, Levy P. Profile of circulating cytokines: impact of OSA, obesity and acute cardiovascular events. Cytokine. 2013;62:210–6.PubMedCrossRefGoogle Scholar
  73. Uriarte G, Paternain L, Milagro FI, Martinez JA, Campion J. Shifting to a control diet after a high-fat, high-sucrose diet intake induces epigenetic changes in retroperitoneal adipocytes of Wistar rats. J Physiol Biochem. 2013;69:601–11.PubMedCrossRefGoogle Scholar
  74. Verbeek J, Spincemaille P, Vanhorebeek I, Van den Berghe G, Vander Elst I, Windmolders P, van Pelt J, et al. Dietary intervention, but not losartan, completely reverses non-alcoholic steatohepatitis in obese and insulin resistant mice. Lipids Health Dis. 2017;16:46.PubMedPubMedCentralCrossRefGoogle Scholar
  75. Walker RW, Allayee H, Inserra A, Fruhwirth R, Alisi A, Devito R, Carey ME, et al. Macrophages and fibrosis in adipose tissue are linked to liver damage and metabolic risk in obese children. Obesity (Silver Spring). 2014;22:1512–9.CrossRefGoogle Scholar
  76. Waterland RA, Travisano M, Tahiliani KG, Rached MT, Mirza S. Methyl donor supplementation prevents transgenerational amplification of obesity. Int J Obes. 2008;32:1373–9.CrossRefGoogle Scholar
  77. Wilding JP, Overgaard RV, Jacobsen LV, Jensen CB, le Roux CW. Exposure-response analyses of liraglutide 3.0 mg for weight management. Diabetes Obes Metab. 2016;18:491–9.PubMedPubMedCentralCrossRefGoogle Scholar
  78. Yang JD, Abdelmalek MF, Pang H, Guy CD, Smith AD, Diehl AM, Suzuki A. Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology. 2014;59:1406–14.PubMedPubMedCentralCrossRefGoogle Scholar
  79. Yang B, Petrick JL, Kelly SP, Graubard BI, Freedman ND, McGlynn KA. Adiposity across the adult life course and incidence of primary liver cancer: the NIH-AARP cohort. Int J Cancer. 2017;141:271–8.PubMedPubMedCentralCrossRefGoogle Scholar
  80. Yoshiji H, Noguchi R, Ikenaka Y, Namisaki T, Kitade M, Kaji K, Shirai Y, et al. Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat. BMC Res Notes. 2009;2:70.PubMedPubMedCentralCrossRefGoogle Scholar
  81. Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y, Racila A, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016a;64:1577–86.PubMedCrossRefGoogle Scholar
  82. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016b;64:73–84.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Institute for Liver and Digestive HealthUniversity College London, Royal Free HospitalLondonUK
  2. 2.Department of Gastroenterology and HepatologyGuy’s and St Thomas’ Hospital, NHS Foundation TrustLondonUK

Personalised recommendations